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Paroxysmal extreme pain disorder (PEPD), previously
known as familial rectal pain (FRP, OMIM 167400), is
an inherited disease causing intense burning rectal,
ocular, and submandibular pain and flushing. Fertle-
man et al. (this issue of Neuron) show that mutations
in SCN9A, the gene encoding the sodium channel
NaV1.7 channels, are responsible for this syndrome.
Together with earlier work implicating a distinct class
of functional mutations in SCN9A in a distinct in-
herited pain syndrome, these results point to NaV1.7
channels as key players in signaling nociceptive infor-
mation and as a potential target for drug therapy of
chronic pain.
Besides inheriting annoying relatives, how could one be
afflicted with inherited pain in the rectum? In this issue of
Neuron, Fertleman et al. (2006) show that paroxysmal
extreme pain disorder (PEPD) is caused by mutations
in sodium channels that are responsible for action po-
tential conduction in peripheral nerves. Thus, PEPD
takes a new place among the ion channelopathies.
Ion channelopathies are usually the result of dominant
mutations that cause gain-of-function effects leading to
hyperactivity of ion channels (Ashcroft, 2000). The first
ion channelopathy to be described was hyperkalemic
periodic paralysis of skeletal muscle, which is caused
by mutations in the skeletal muscle sodium channel
NaV1.4 (Venance et al., 2006). Subsequent work has
shown that hypokalemic periodic paralysis and para-
myotonia congenita of skeletal muscle are also caused
by mutations in NaV1.4 channels. Moreover, cardiac
arrhythmias in long-QT syndrome type 3 and Brugada
syndrome are caused by mutations in NaV1.5 channels
expressed in the heart (Keating and Sanguinetti, 2001),
and generalized epilepsy with febrile seizures plus,
benign familial neonatal-infantile convulsions, severe
myoclonic epilepsy in infancy, and one form of familial
hemiplegic migraine are all caused by mutations in
NaV1.1 or NaV1.2 channels in central neurons (Meisler
and Kearney, 2005).
Although sodium channels transmit pain signals from
peripheral nociceptive nerve endings back to the dorsal
root ganglion neurons and the spinal cord, the recogni-
tion of involvement of these channels in inherited pain
syndromes is quite recent. Primary erythermalgia (PE)
an inherited syndrome of burning pain and flushing in
the extremities, is caused by mutations in the NaV1.7
channel (Yang et al., 2004; Waxman and Dib-Hajj,
2005), which is expressed primarily in peripheral neu-
rons and their axons. These mutations enhance the ac-
tivation of sodium channels. In contrast, the mutations
that cause PEPD impair inactivation of NaV1.7 channels
(Fertleman et al., 2006). Thus, there is a well-defined
genotype/phenotype correlation between these two
distinct peripheral pain syndromes.Mutations that cause ion channelopathies are scat-
tered widely through the sodium channel structure
(Figure 1), but there is a concentration of mutations in
regions involved in activation and inactivation gating.
Activation of sodium channels and other voltage-gated
ion channels is initiated by a voltage-driven conforma-
tional change in the voltage sensor domain composed
of the S1–S4 segments and their connecting loops in
each of the four homologous repeat domains (Figure 1;
Catterall, 2000). Depolarization exerts a force on the
positively charged arginine or lysine residues in the S4
segment (Figure 1, green), which serve as gating
charges. This force leads to outward and rotational
motion of the S4 segment and coordinated movement
of the S1, S2, and S3 segments around S4 (Tombola
et al., 2006; Yarov-Yarovoy et al., 2006). These structural
changes cause opening of the transmembrane pore by
pulling on the pore-forming S5 and S6 segments (Fig-
ure 1, red) and causing them to bend at a hinge glycine
residue. Following activation, the inactivation gate
formed by the intracellular loop-connecting domains III
and IV (Figure 1) folds into the intracellular mouth of
the pore and prevents further sodium conductance (Cat-
terall, 2000). The closed inactivation gate interacts with
the S4–S5 loops in domains III and IV and the end of
the S6 segment in domain IV on the intracellular surface
of the sodium channel (Catterall, 2000).
As illustrated by the symbols in Figure 1A (red circles),
mutations that cause paramyotonia congenita and re-
lated myotonias are primarily located in the inactivation
gate loop connecting homologous domains III and IV,
the inactivation gate receptor regions in the S4–S5 intra-
cellular loops within domains III and IV and the C-termi-
nal end of the IVS6 segment, and the S4 segment in
domain IV that couples activation to inactivation. Failure
of inactivation in paramyotonia congenita mutants
causes repetitive reopening of these channels and
generates the repetitive action potentials that cause
the disease. Mutations in these regions are also ob-
served in NaV1.5 channels in inherited cardiac arrhyth-
mias (Figure 1B) and in NaV1.1 channels in generalized
epilepsy with febrile seizures plus (Figure 1C). This con-
centration of mutations in regions that can directly
impair the inactivation process is consistent with the
conclusion that hyperactivity of sodium channels is
most easily generated by block of inactivation.
This preferential involvement of mutations that impair
inactivation is particularly clear in the case of PEPD (Fer-
tleman et al., 2006). Of the eight mutations that cause
PEPD, three are located in the inactivation gate itself,
three in the S4–S5 loop in domain III, and one in the
S4–S5 loop in domain IV (Figure 1D, yellow circles).
These disease mutations map almost exactly onto the
structure-function results for sodium channel inactiva-
tion (Catterall, 2000). All of these mutations cause noni-
nactivating sodium currents in NaV1.7 channels, which
likely cause the PEPD syndrome by inducing repetitive
firing in peripheral nerves that conduct pain information.
In contrast, the locations of the mutations that cause PE
reveal no overlap with those that cause PEPD. The
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744Figure 1. Inherited Human Disease Mutations of Voltage-Gated So-
dium Channels
The four homologous domains (I–IV) of the pore-forming a subunit of
sodium channels are illustrated as transmembrane folding diagrams
in which cylinders represent a-helical transmembrane segments
S1–S6. Green cylinder, S4 voltage sensor; red cylinders, S5–S6
pore-forming segments. Missense mutations in the Online Mende-
lian Inheritance of Man Database (OMIM) that lead to inherited chan-
nelopathies of sodium channels are represented by superimposed
symbols. Not illustrated are nonsense mutations and insertion/dele-
tion mutations that lead to truncations or loss of expression of func-
tional channels, which in the case of severe myoclonic epilepsy in
infancy comprise the vast majority.
(A) Mutations of the skeletal muscle sodium channel, NaV1.4. Red
circles, mutations linked to paramyotonia congenita, myotonia con-
genital, and myotonia fluctuans; yellow stars, hyperkalemic periodic
paralysis mutations; blue squares, normo- and hypokalemic periodic
paralysis mutations (P1158S mutation not shown); green triangle,
mutation linked to myasthenic syndrome.
(B) Locations of inherited mutations of cardiac sodium channel,
NaV1.5. Red circles, mutations associated with long-QT syndrome
3; blue squares, Brugada syndrome mutations; yellow triangles, mu-
tations linked to sick sinus syndrome, progressive familial heart
block, ventricular fibrillation, or cardiac conduction effect.
(C) Locations of inherited disease mutations of brain sodium chan-
nels, NaV1.1 and NaV1.2. Red circles, mutations on NaV1.1 asso-
ciated with generalized epilepsy with febrile seizures plus, severe
myoclonic epilepsy in infancy, intractable childhood epilepsy with
generalized tonic-clonic seizures, familial hemiplegic migraine, and
familial febrile convulsions; blue squares, NaV1.2 mutations linked
to benign familial neonatal-infantile seizures and febrile seizures
associated with afebrile seizures.erythermalgia mutations are located in regions of the so-
dium channel involved in activation and have specific ef-
fects on activation and deactivation gating (Waxman
and Dib-Hajj, 2005). These results demonstrate a clear
molecular basis for the genotype/phenotype correlation
between mutations in NaV1.7 channels and the different
effects they cause in PEPD and PE.
The essential roleofNaV1.7 channels inpain, asdemon-
strated by the mutations in PE and PEPD, points to these
channels as an ideal drug target for treatment of chronic
pain. Although acute pain is well treated by local applica-
tion of local anesthetics or by systemic treatment with
nonsteroidal anti-inflammatory drugs or opiate drugs,
these approaches are not successful for intense chronic
pain. Local anesthetics cannot be applied repeatedly to
the source of chronic pain in most cases, anti-inflamma-
tory drugs are usually not sufficient to block intense
chronic pain, and repeated use of opiates leads to toler-
ance and addiction. Effective treatment of chronic pain
is therefore an important unmet medical need. A recent
symposium at the National Medicinal Chemistry Meeting
in Seattle, Washington, USA (June, 2006; http://wiz2.
pharm.wayne.edu/nmcs30abstracts2006.pdf, pp. 33–36)
revealed much progress toward development of novel,
high-affinity sodium channel blockers that may be useful
for treatment of this difficult condition. Hopefully, we can
look forward to new therapeutic agents that will be help-
ful to patients with PEPD, PE, and the much more com-
mon chronic and neuropathic pain from traumatic injury,
degenerative spine syndromes, and medical conditions
such as arthritis, diabetes, cancer, Herpes infection,
and many others.
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(D) Locations of inherited mutations of the peripheral nerve
sodiumchannel, NaV1.7. Blue squares, PE mutations; yellow circles,
PEPD mutations.
